{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Biomarker-Driven Cancer Care Is Not Reaching All Americans

Activity Steps

Purpose of Activity

To explore the current inequity in cancer care surrounding a paradigm shift toward tissue- agnostic treatment based on tumor biology.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the emerging targeted therapies of precision medicine available for cancer treatment.
  2. Analyze the reimbursement and practice gap barriers hindering access to cancer biomarker testing.
  3. Identify ways to narrow the access gap and ensure the equitable delivery of precision medicine to all Americans.
Price: $12.95


  • ASCLS | P.A.C.E. 0.5 CH

Lippincott Williams & Wilkins is an approved P.A.C.E. annual provider for continuing education credit to clinical laboratory professionals.

CA Accrediting Agency No: 0001

Test Code: OT0920CLS
Published: 11/1/2020
Expires: 1/12/2022
Required Passing Score: 7/10 (70%)
Authors: Peggy Eastman